35 results about "Chronic atrial fibrillation" patented technology

At the present time, physicians often treat patients with atrial fibrillation (AF) using radiofrequency (RF) catheter systems to ablate conducting tissue in the wall of the Left Atrium of the heart around the ostium of the pulmonary veins. These systems are expensive and take time consuming to use. The present invention circular ablation system CAS includes a multiplicity of expandable needles that can be expanded around a central axis and positioned to inject a fluid like ethanol to ablate conductive tissue in a ring around the ostium of a pulmonary vein quickly and without the need for expensive capital equipment. The expansion of the needles is accomplished by self-expanding or balloon expandable structures. The invention includes centering means so that the needles will be situated in a pattern surrounding the outside of the ostium of a vein. Also included are members that limit the distance of penetration of the needles into the wall of the left atrium. The present invention also has application to ablating tissue around the ostium of a renal artery for the treatment of hypertension.

An ablation therapy system and systematic method is provided for treating continuous atrial fibrillation. The therapy system includes a Multi-Channel RF Ablation Generator, an ECG interface, an assembly of at least three ablation catheters, and an ECG interface operably coupling and interfacing the catheters to both an ECG unit and the RF Ablation Generator. The systematic method includes transseptally accessing the Left Atrium (LA) through the septum of the patient's heart, and performing an endocardial pulmonary vein ablation procedure on the pulmonary vein ostial tissue surrounding one or more pulmonary veins in a manner treating aberrant conductive pathways therethrough. After performing the pulmonary vein ablation, the method further includes performing an endocardial atrial septum ablation procedure on the septal tissue in a manner treating aberrant conductive pathways therethrough.

A method for treating atrial fibrillation in an atrium of a heart includes (a) acquiring an image or map of the atrium; (b) displaying the image or map of the atrium; (c) marking at least one feature on the image or map; (d) calculating dimensions of the at least one feature; (e) identifying one or more points on or within the atrium for treatment as part of a treatment plan; (f) determining paths to the one or more points on or within the atrium for treatment; (g) simulating insertion of a sheath into the atrium; (h) simulating insertion of a medical device through the sheath and into the atrium; (i) verifying that the one or more points on or within the atrium can be accessed for treatment; (j) computing an overall surface area of the atrium; (k) calculating an estimated area not treated in the atrium based on the treatment plan; (l) assessing whether macro-reentrant circuits can exist in the estimated area not treated in the atrium; (m) repeating steps (e)-(l) in the event step (l) indicates that macro-reentrant circuits can exist in the estimated area not treated in the atrium; and (n) implementing the treatment plan.

A real-time arrhythmia discrimination method is used in smartphones, which can discriminate between NSR, AF, PACs and PVCs using pulsatile time series collected from a smartphone's camera. To increase the sensitivity of AF detection and add the new capabilities of PVC and PAC identification, the arrhythmia discrimination method of these teachings combines Root Mean Square of Successive RR Differences (RMSSD), Shannon Entropy (ShE) and turning point ratio (TPR), with the Poincare plot, and utilizes the features of pulse rise / fall time and amplitude for arrhythmia discrimination.

The disclosure describes techniques for delivering electrical stimulation to decrease the ventricular rate response during an atrial tachyarrhythmia, such as atrial fibrillation. AV nodal stimulation is employed during an atrial tachyarrhythmia episode with rapid ventricular conduction to distinguish ventricular tachyarrhythmia from supraventricular tachycardia and thereby prevent delivering inappropriate therapy to a patient.

Energy is transmitted noninvasively to a patient using electrode-based stimulation devices or magnetic stimulation devices that are designed to non-invasively stimulate nerves selectively. The devices produce impulses that are used to treat atrial fibrillation, by stimulating a vagus nerve of a patient. The devices are also used to forecast the imminent onset of atrial fibrillation and then avert it by stimulating a vagus nerve.

A method for the treatment of a patient for the purpose of lowering blood pressure and / or treating cardiac arrhythmias, particularly atrial fibrillation includes the insertion of an ablation catheter into the lumen of a renal artery. The ablation catheter is equipped with an electrode that can stimulate the wall tissue in the renal artery to help identify the location of a renal nerve. High-frequency stimulation of the renal nerve causes a decrease in the blood pressure of the patient thereby indicating that a renal nerve is nearby. The ablation catheter is used to ablate the renal nerve using radiofrequency, ultrasound, microwave energy or cryogenic cooling. An irrigated ablation catheter may be used to decrease damage to cells in the wall of the lumen of the renal artery other than the renal nerve, such as the endothelial cells.

The present invention relates to a method for the treatment or prevention of atrial fibrillation and / or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

The invention relates to a method for the determination of the time from onset of atrial fibrillation to presentation in a patient comprising the steps of: providing a sample of a bodily fluid of said patient, determining the level of proANP (SEQ ID NO: 1) or fragments thereof in said sample, correlating the level of proANP or fragments thereof to the time from the onset of atrial fibrillation to presentation of said patient, wherein said fragments have a length of at least 6 amino acid residues.